sustained virologic response

January 12, 2017January 12, 2017

AbbVie’s One-Pill Combo Therapy Shows Promise for Hepatitis C in Japanese Trial

Hepatitis C, News

AbbVie’s new hepatitis C treatment candidate, a one tablet combination of the investigational drugs glecaprevir and pibrentasvir, harnessed the infection in all patients who completed a Japanese study. The treatment, ... Read more

November 17, 2016November 17, 2016

AbbVie’s HCV Therapy Looks Highly Effective in Patients with Severe Kidney Disease

Hepatitis C, News

AbbVie recently announced positive results for the company’s investigational regimen of glecaprevir/pibrentasvir (G/P) in treating patients with chronic hepatitis C virus (HCV). Results are from the EXPEDITION-4 study (NCT02651194), an open-label Phase ... Read more

October 25, 2016October 25, 2016

Combo Anti-Viral Treatment for Chronic Hepatitis C Shows Efficacy in Phase 3 Studies

Hepatitis C, News

Top-line results from four global Phase 3 clinical studies (POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4), led by Gilead Sciences, showed that the combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) — inhibitors of viral activity — can ... Read more